Clinical Trials
95 trialsTesting the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
MOONRAY-01
Eli Lilly and Company
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Washington University School of Medicine
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Washington University School of Medicine
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Cancer Research and Biostatistics Clinical Trials Consortium
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Biocity Biopharmaceutics Co., Ltd.
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
Augusta University
Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV
National Cancer Center, Korea
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Venetoclax and Irinotecan in Relapsed/Refractory SCLC
Virginia Commonwealth University
A Single-arm, Phase â…¡ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
First People's Hospital of Hangzhou
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Guangdong Association of Clinical Trials
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
United Therapeutics
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy(Irinotecan Plus Platinum)and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer(SCLC)
Peking Union Medical College Hospital
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
Guizhou Medical University
Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC
Leo W. Jenkins Cancer Center
Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
Beijing Chest Hospital
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
SWOG Cancer Research Network
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
NivoPlus
Western Regional Medical Center
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
New Mexico Cancer Research Alliance
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Merrimack Pharmaceuticals
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
University of California, Davis
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
University of Alabama at Birmingham
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Northwestern University
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
University of Miami
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
Guangdong Association of Clinical Trials
A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC
Japan Clinical Oncology Group
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals